These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 12632082

  • 1. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
    Tanabe K, Kim R, Inoue H, Emi M, Uchida Y, Toge T.
    Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
    [Abstract] [Full Text] [Related]

  • 2. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma.
    Kim R, Tanabe K, Uchida Y, Emi M, Toge T.
    Int J Mol Med; 2003 Jun; 11(6):799-804. PubMed ID: 12736725
    [Abstract] [Full Text] [Related]

  • 3. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells.
    Kim R, Tanabe K, Emi M, Uchida Y, Toge T.
    Cancer; 2005 May 15; 103(10):2199-207. PubMed ID: 15830342
    [Abstract] [Full Text] [Related]

  • 4. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer.
    Rait AS, Pirollo KF, Rait V, Krygier JE, Xiang L, Chang EH.
    Cancer Gene Ther; 2001 Oct 15; 8(10):728-39. PubMed ID: 11687896
    [Abstract] [Full Text] [Related]

  • 5. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R, Tanabe K, Emi M, Uchida Y, Osaki A, Toge T.
    Int J Oncol; 2005 Apr 15; 26(4):1025-31. PubMed ID: 15753998
    [Abstract] [Full Text] [Related]

  • 6. Death receptor-dependent and -independent pathways in anticancer drug-induced apoptosis of breast cancer cells.
    Kim R, Tanabe K, Emi M, Uchida Y, Toge T.
    Oncol Rep; 2003 Apr 15; 10(6):1925-30. PubMed ID: 14534720
    [Abstract] [Full Text] [Related]

  • 7. Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma.
    Kim R, Emi M, Tanabe K, Toge T.
    Cancer; 2004 Nov 15; 101(10):2177-86. PubMed ID: 15476281
    [Abstract] [Full Text] [Related]

  • 8. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
    Wang Z, Goulet R, Stanton KJ, Sadaria M, Nakshatri H.
    Anticancer Res; 2005 Nov 15; 25(3c):2367-79. PubMed ID: 16080463
    [Abstract] [Full Text] [Related]

  • 9. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD.
    Clin Cancer Res; 2000 Jul 15; 6(7):2891-902. PubMed ID: 10914739
    [Abstract] [Full Text] [Related]

  • 10. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K.
    Cancer Res; 2006 Jun 01; 66(11):5836-46. PubMed ID: 16740723
    [Abstract] [Full Text] [Related]

  • 11. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
    Sawada S, Mese H, Sasaki A, Yoshioka N, Matsumura T.
    Cancer Chemother Pharmacol; 2003 Jun 01; 51(6):505-11. PubMed ID: 12709826
    [Abstract] [Full Text] [Related]

  • 12. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
    Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K.
    Clin Cancer Res; 2005 Sep 01; 11(17):6382-9. PubMed ID: 16144943
    [Abstract] [Full Text] [Related]

  • 13. [Therapeutic potential of antisense (AS) Bcl-2 as a chemosensitizer for patients with gastric and breast carcinoma].
    Kim R, Emi M, Matsuura K, Tanabe K.
    Gan To Kagaku Ryoho; 2005 Oct 01; 32(11):1540-5. PubMed ID: 16315863
    [Abstract] [Full Text] [Related]

  • 14. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
    Arisan ED, Kutuk O, Tezil T, Bodur C, Telci D, Basaga H.
    Breast Cancer Res Treat; 2010 Jan 01; 119(2):271-81. PubMed ID: 19238538
    [Abstract] [Full Text] [Related]

  • 15. Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment.
    Sun J, Xu Y, Song S, Wu Z, Duan H.
    Pharm Biol; 2011 Nov 01; 49(11):1167-72. PubMed ID: 22014264
    [Abstract] [Full Text] [Related]

  • 16. Targeted therapy against Bcl-2-related proteins in breast cancer cells.
    Emi M, Kim R, Tanabe K, Uchida Y, Toge T.
    Breast Cancer Res; 2005 Nov 01; 7(6):R940-52. PubMed ID: 16280040
    [Abstract] [Full Text] [Related]

  • 17. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H, Nelson C, Rennie PS, Gleave ME.
    Cancer Res; 2000 May 01; 60(9):2547-54. PubMed ID: 10811138
    [Abstract] [Full Text] [Related]

  • 18. The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review).
    Kim R, Tanabe K, Uchida Y, Osaki A, Toge T.
    Oncol Rep; 2002 May 01; 9(1):3-9. PubMed ID: 11748447
    [Abstract] [Full Text] [Related]

  • 19. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.
    Schwartz GK, Farsi K, Maslak P, Kelsen DP, Spriggs D.
    Clin Cancer Res; 1997 Sep 01; 3(9):1467-72. PubMed ID: 9815832
    [Abstract] [Full Text] [Related]

  • 20. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
    Kastl L, Brown I, Schofield AC.
    Breast Cancer Res Treat; 2012 Jan 01; 131(2):445-54. PubMed ID: 21399894
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.